The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation
Pharmacogenetics and genomics Aug 15, 2017
Lloberasm N, et al. – The physicians examined the associations of single–nucleotide polymorphisms (SNPs) in drug–metabolizing enzymes (CYP3A) with tacrolimus (Tac) pharmacokinetics in renal transplant recipients. They observed a major influence of the combined CYP3A4 and CYP3A5 genotype of renal transplant recipients on the Tac dose required to reach the target exposure.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins